Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.46 |
| ▸ | KDR | P35968 | 13/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741974 | 0.91 | MET (0.46) | METKDRKITFLT3AXL | |
| SCHEMBL1743441 | 0.87 | POLB (0.48) | METKDRKITFLT3AXL | |
| SCHEMBL1741986 | 0.87 | MET (0.43) | METKDRKITFLT3AXL | |
| SCHEMBL1743562 | 0.86 | MET (0.45) | METKDRKITFLT3AXL | |
| SCHEMBL1742657 | 0.86 | MAPT (0.49) | METKDRKITFLT3AXL | |
| SCHEMBL1741316 | 0.85 | UTS2R (0.45) | METKDRKITFLT3AXL | |
| SCHEMBL1741960 | 0.85 | MET (0.51) | METKDRKITFLT3AXL | |
| SCHEMBL1741248 | 0.85 | MET (0.42) | METKDRKITFLT3AXL | |
| SCHEMBL1741954 | 0.83 | MET (0.43) | METKDRKITFLT3AXL | |
| SCHEMBL1741966 | 0.83 | MAPT (0.45) | METKDRKITFLT3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563579-B2 | α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2013-10-22 | — | — | US | claimed |
| EP-2387575-B1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2387575-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2011-11-23 | — | — | EP | claimed |
| US-D647030-S1 | Automobile tire tread | THE YOKOHAMA RUBBER CO., LTD (JP) | 2011-10-18 | — | — | US | claimed |
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ALPHARMAGEN LLC | 2010-07-29 | — | — | US | claimed |
| WO-2010083444-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL, LLC (US) | 2010-07-22 | — | — | WO | claimed |
| US-8975407-B2 | α7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140194462-A1 | Alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ANVYL LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8563579-B2 | α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2387575-B1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2387575-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-D647030-S1 | Automobile tire tread | THE YOKOHAMA RUBBER CO., LTD (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ALPHARMAGEN LLC | 2010-07-29 | — | — | US | disclosed |
| WO-2010083444-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL, LLC (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | CHRNA7, CHRNA1, CHRNG | MET 4323/4885KDR 4098/4885KIT 3896/4885 |
| US-20140194462-A1 | Alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | CHRNA7, CHRNA1, CHRNG | MET 4323/4885KDR 4098/4885KIT 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.